LAG-3 demonstrated a notable 2.7-fold increase in expression in TIL-derived CD8+ T cells compared to their peripheral counterparts (PBMCs: 3.2%; TILs: 8.6%), further supporting the accumulation of inhibitory receptor-expressing T cells within the tumor site. The gene discussed is CD8A; the disease is neoplasm.